Optimi MDMA capsules intended for two clinical trials and Australian commercial supply have been manufactured, the company announced on October 20, 2026. The completed batch is expected to support a proposed Canadian Phase 3 study of post-traumatic stress disorder, a trial in Israel and an Australian shipment planned before the end of 2026.
Key Takeaways
- Manufacturing is complete, but the announced trial use and next Australian shipment remain prospective.
- The proposed Canadian Phase 3 trial is expected to begin in 2027 and enroll up to 100 participants.
- Optimi’s MDMA products have not received Canadian market authorization.
Table of Contents
- Optimi MDMA production supports three programs
- Canadian Phase 3 study targets veterans and frontline workers
- Australia shipment planned as Israeli trial supply continues
- Conclusion
Optimi MDMA production supports three programs
Optimi Health’s production announcement says the finished capsules were made at its good manufacturing practice facility in Princeton, British Columbia, under its Health Canada Drug Establishment Licence. The company said the batch is sufficient for the three intended programs.
The manufacturing milestone brings together two different uses of the same product: investigational treatment in clinical trials and commercial supply through Australia’s regulated prescribing framework. Completing production does not mean the planned shipments have occurred or that clinical efficacy has been established.
| Item | Details |
|---|---|
| Canadian trial dosage formats | Synthetic MDMA hydrochloride supplied in two dosage formats. |
| Treatment schedule | Two supervised MDMA-and-psychotherapy sessions spaced several weeks apart. |
| Primary efficacy endpoint | Change in the Clinician-Administered PTSD Scale, known as CAPS-5. |
Canadian Phase 3 study targets veterans and frontline workers
The proposed Canadian study is intended to recruit up to 100 participants across multiple sites, focusing on veterans and current or former frontline workers. Optimi expects the trial to begin in 2027 and evaluate the safety and efficacy of MDMA-assisted therapy for PTSD.
Participants are expected to receive synthetic MDMA hydrochloride alongside psychotherapy, with follow-up assessments after the final treatment session. The planned design includes the treatment and measurement details below.
Although the announcement describes the trial as Health Canada-authorized, that is distinct from permission to market the drug. MDMA-assisted therapy’s safety and efficacy for PTSD remain under investigation in Canada, and none of Optimi’s MDMA products has received Health Canada market authorization.
Australia shipment planned as Israeli trial supply continues
Optimi said it has received Australian import permits for MDMA and plans its next shipment before the end of 2026. The shipment is intended to supply clinics and pharmacies through Optimi Australia.
Australia permits authorized clinicians to prescribe MDMA for PTSD under the Therapeutic Goods Administration’s Authorised Prescriber Scheme. That existing commercial access route differs from the proposed Canadian Phase 3 research program.
In Israel, Optimi supplies capsules for MAPS Israel’s Healing October 7th project. The company said the project includes a PTSD clinical trial formally approved by the Israeli Ministry of Health, a supply arrangement previously announced on November 26, 2025.
Conclusion
The next scheduled milestone is the Australian shipment targeted before the end of 2026, followed by the proposed Canadian trial start in 2027. Both remain company plans, separate from the completed manufacturing batch.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
